Hepion Pharmaceuticals, Inc. (HEPA) Insider Buying
Every C-suite and executive open-market purchase of Hepion Pharmaceuticals, Inc. stock we've tracked from SEC Form 4 filings — each scored on our six-factor model. Not financial advice.
| Ticker | Insider | Role | Value | Filed | Signal | Score |
|---|---|---|---|---|---|---|
| HEPA Hepion Pharmaceuticals, Inc. | Stetz Gary S. | Interim CEO | $50,000 | Apr 27, 2026 | AVOID | 34 |
| HEPA Hepion Pharmaceuticals, Inc. | LoPriore Vincent S | Executive Chairman | $200,000 | Apr 27, 2026 | AVOID | 23 |
What this page tracks
This is a live record of open-market stock purchases by directors and officers of Hepion Pharmaceuticals, Inc., sourced directly from SEC EDGAR Form 4 filings. We only count open-market buys — not option exercises or grants — because a personal-money purchase is the cleanest insider conviction signal.
Each filing is scored with our six-factor methodology (fundamentals, financials, technicals, conviction, CEO history, and cluster activity). See how the resulting signals performed against the S&P 500 on the track record, or browse this week's insider buys and the full signal screener.
Get new HEPA signals the morning they file
One email a day with newly scored CEO insider-buying signals. $3.99/mo, cancel anytime.
Start Free 7-Day Trial